ArticleBMJ case reports2018
Olmesartan-associated severe gastritis and enteropathy.
Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Not Only Enteropathy: The Overlooked "Gastric Side" of Olmesartan.Clinical case reports · 2026Article
- Article
- Olmesartan-associated gastroduodenitis that was detected on endoscopic follow-up.Clinical journal of gastroenterology · 2025Article
- Olmesartan-Induced Gastropathy: An Important Cause to Think about in Refractory Peptic Ulcer Disease.GE Portuguese journal of gastroenterology · 2025Article
- Olmesartan-associated Gastritis Observed Over Time.Internal medicine (Tokyo, Japan) · 2025Article
- Drug-induced mucosal alterations observed during esophagogastroduodenoscopy.World journal of gastroenterology · 2024Review
- Olmesartan-Induced Enteropathy: A Rare Case of Chronic Diarrhea.Case reports in medicine · 2024Article
- The histological spectrum of ARB-induced gastritis.Histopathology · 2022Article
- Article
- Autoimmune Gastritis Treated With Mycophenolate Mofetil.ACG case reports journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olmesartan is an angiotensin II receptor antagonist, used in the treatment of hypertension. We report a case of olmesartan-associated severe gastritis with enteropathy in a 74-year-old woman who presented with mainly upper gastrointestinal symptoms. There was significant endoscopic improvement in the mucosal inflammation on stopping the drug. Subsequent gastroscopy showed mucosal healing and normal gastric and duodenal mucosa. To our knowledge, this is the first case report of olmesartan-associated gastritis and enteropathy predominantly involving and affecting the whole of stomach with limited small bowel involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.